TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Depression Treatment Following Coronary Artery Bypass Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Recently underwent CABG (combined or redo procedure) at one of 8 Pittsburgh area study hospitals~* A PHQ score greater than 10 OR if nondepressed control, a PHQ score less than 5 at both 2 days post CABG to the date of discharge following CABG and when reassessed 2 weeks after hospital discharge~* Folstein Mini-Mental State Examination (MMSE) score greater than or equal to 24~* Able to be evaluated and treated for depression as an outpatient post CABG~* Has a household telephone~Exclusion Criteria:~* Presently in treatment with a mental health specialist~* Actively suicidal~* History of psychotic illness~* History of bipolar illness according to subject self-report and past medical history~* Current alcohol dependence or other substance abuse as evidenced by chart review and the CAGE questionnaire~* Organic mood syndromes, including those secondary to medical illness or drugs~* Presence of non-cardiovascular conditions that are likely to be fatal within 1 year~* Unstable medical condition as indicated by history, physical, and/or laboratory findings~* Previous enrollment in the study cohort~* Non-English speaking, illiterate, or possessing any other communication barrier~* If nondepressed control, current or previous diagnosis or treatment of depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Depressed Intervention (Type: EXPERIMENTAL): Telephone-based, nurse-delivered Collaborative Care program for depression; Involving: Psychoeducation; workbook for depression self-care; initiation or adjustment of antidepressant pharmacotherapy prescribed under their PCPs' direction; referral to mental health specialist
- Depressed Usual Care (Type: ACTIVE_COMPARATOR): Usual care for depression; feedback of the depression finding by the study team
- Non-Depressed Control Group (Type: NO_INTERVENTION): Non-depressed control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* BMI between 18.0 and 29.9 kg/m2, both inclusive, when rounded to the nearest tenth~Exclusion Criteria:~* A medical history and/or condition that is considered significant~* Clinically significant allergic reactions, hypersensitivity~* History or current infection of hepatitis B virus (except for past resolved infection), hepatitis C virus, human immunodeficiency virus, or syphilis~* Active or latent Tuberculosis~* History of malignancy~* Previous monoclonal antibody or fusion protein treatment, or current use of any biologic~* Planning to be pregnant or father a child or donate sperm within 5 month after administration~* Undergone treatment with an investigational drug or participated in another clinical trial within 90 days or 5 half-lives (whichever is longer)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P17 (Type: EXPERIMENTAL): a single subcutaneous (SC) injection via pre-filled syringe (PFS)
- US-licensed Humira (Type: ACTIVE_COMPARATOR): a single subcutaneous (SC) injection via pre-filled syringe (PFS)
- EU-approved Humira (Type: ACTIVE_COMPARATOR): a single subcutaneous (SC) injection via pre-filled syringe (PFS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ≥18 years of age at the time of the screening visit~2. Diagnosis of HeFH (Heterozygous familial hypercholesterolemia)~3. Currently undergoing LDL (low-density lipoprotein) apheresis therapy QW (weekly) or Q2W (every 2 weeks) or at least 8 weeks prior to the screening visit~Exclusion Criteria:~1. Homozygous FH (familial hypercholesterolemia)~2. Background medical LMT (lipid-modifying therapy) (if applicable) that has not been stable for at least 8 weeks prior to the screening visit~3. LDL apheresis schedule/ apheresis settings that have not been stable for at least 8 weeks prior to the screening visit~4. An LDL apheresis schedule other than QW to Q2W~5. Initiation of a new exercise program or exercise that has not remained stable within 8 weeks prior to the screening visit (week -2)~6. Initiation of a new diet or a diet that has not been stable within 8 weeks prior to the screening visit (week -2)~7. Use of nutraceuticals or over-the-counter therapies known to affect lipids, at a dose/amount that has not been stable for at least 8 weeks prior to the screening visit (week -2), or between the screening and randomization visit~8. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins~9. Known history of a positive test for human immunodeficiency virus~10. Use of any active investigational drugs within 1 month or 5 half-lives of screening, whichever is longer~11. Patients who have been treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in any other clinical studies~12. Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Double Blind Period) (Type: EXPERIMENTAL): Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
- Alirocumab 150 mg Q2W (Double Blind Period) (Type: EXPERIMENTAL): Alirocumab 150 mg SC injection Q2W up to Week 16.
- Alirocumab 150 Q2W (Open Label Treatment Period) (Type: EXPERIMENTAL): Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Recombinant Human Prolactin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy Subjects will meet the following criteria:~1. 18 to 40 years of age~2. Normal weight (BMI 17 to £ 30 kg/m2)~3. Good general health~4. On no medications for at least 3 months before the study~5. Regular menstrual cycles every 25-35 days with ovulation documented by a luteal phase progesterone level~6. No evidence of androgen excess~7. Normal TSH, prolactin and hematocrit~8. No current interest in conception~9. No history of osteoporosis~10. No use of medications known to affect bone turnover~11. No alcoholism~12. No smoking~13. No history of medical problems or treatment known to affect bone turnover.~Exclusion Criteria:~Subjects will be excluded for pregnancy or evidence of breast masses.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- recombinant human prolactin (Type: EXPERIMENTAL): Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline placebo subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-65 years old (including 18 and 65 years old), healthy male subjects.~* Body mass index (BMI) within the range 19-28kg/m2.~* History, physical examination, laboratory tests and test related items of inspection were normal or mildly abnormal clinically insignificant.~* Volunteered to participate in this clinical trial, capable of giving written informed consentan.~* The subject (including the subject's partner) takes effective contraceptive measures.~Exclusion Criteria:~* Nervous/mental, respiratory system, cardiovascular system, digestive system, blood and lymphatic system, endocrine system, skeletal and muscular system diseases, liver and kidney dysfunction, or any other diseases and physiological conditions that may affect the results of the study.~* Occurred or suffering from osteomyelitis or ONJ (mandibular necrosis) previously.~* Clinical laboratory abnormalities of clinical significance, or other clinical findings suggest clinically significant following diseases (including, but not limited to the gastrointestinal tract, kidney, liver, nerve, blood, endocrine, cancer, lung, immune, mental or cardiovascular disease).~* Subject has viral hepatitis (including hepatitis B and hepatitis C), AIDS antibodies, and Treponema pallidum antibodies.~* Those who have used the following drugs within 1 month or 5 half-lives (whichever is longer) before participating in this study, including but not limited to: estrogen-containing contraceptives, bisphosphonates, fluoride, hormone replacement Treatment (ie tibolone, estrogen, estrogen-like compounds, such as raloxifene), calcitonin, strontium, parathyroid hormone or its derivatives, vitamin D supplements (\>1000 IU/day), corticosteroids (inhaled or topical corticosteroids can be used 2 weeks before enrollment), anabolic hormone drugs, calcitriol, diuretics.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- MW031 (Type: EXPERIMENTAL): MW031 injection (60mg) by subcutaneous injection once on the first day of treatment.
- Prolia® (Type: ACTIVE_COMPARATOR): Prolia® injection (60mg) by subcutaneous injection once on the first day of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Body mass index (BMI) below or equal to 35.0 kg/m2~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)~* Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IDeg 100U/mL 0.4U/kg (Type: EXPERIMENTAL): None
- IDeg 100U/mL 0.6U/kg (Type: EXPERIMENTAL): None
- IDeg 100U/mL 0.8U/kg (Type: EXPERIMENTAL): None
- IDeg 200U/mL 0.6U/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bifocal Lenses In Nearsighted Kids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 7 to 11 years, inclusive, at baseline examination~* -0.75 to -5.00 D, inclusive, spherical component, cycloplegic autorefraction~* ≤1.00 DC, cycloplegic autorefraction~* ≥ 2.00 D difference between the sphere components of the two eyes (anisometropia), cycloplegic autorefraction~* 0.1 logMAR or better best-corrected visual acuity in each eye~* 0.1 logMAR or better visual acuity OU distance and near with a +2.50 D add contact lens~* +2.50 D add lens provides adequate fit with respect to movement and centration~Exclusion Criteria:~* Eye disease or binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.)~* Systemic disease that may affect vision, vision development, or contact lens wear (eg, diabetes, Down syndrome, etc.)~* Previous gas permeable, soft bifocal, or orthokeratology contact lens wear or bifocal/PAL spectacle wear (longer than 1 month of wear)~* Previous or current participation in myopia control studies~* Chronic use of medications that may affect immunity, such as oral or ophthalmic corticosteroids for ocular or systemic diseases~* Issues that may interfere with the ability to participate over the next 3 years

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Biofinity (Type: ACTIVE_COMPARATOR): Soft spherical contact lens
- Biofinity Multifocal D +1.50 add (Type: EXPERIMENTAL): The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power
- Biofinity Multifocal D +2.50 add (Type: EXPERIMENTAL): The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 12 to 21 years.~2. HbA1C less than 9%~3. Subjects must be on intensive insulin management~4. Tanner stage greater than or equal to 3~5. Having Type 1 Diabetes for at least one year~6. Type 1Diabetes defined by ADA criteria and having at least one of the following antibodies a. Anti-GAD (glutamic acid decarboxylase) b. Anti-islet cell 512 (ICA512) c. Anti-insulin~7. Willing to give consent.~Exclusion Criteria:~1. Type 2 diabetes.~2. Having any other chronic condition except hypothyroidism stable on medications.~3. On chronic medications that may affect glucose excursions.~4. Anemia as defined as Hb less than 9 gm/dl.~5. Abnormal amylase, lipase or creatinine (twice normal).~6. Abnormal Liver function tests(three times above normal)~7. Unsupportive family environment as determined by clinicians and/or social workers.~8. Pregnant or lactating mothers

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Pramlintide + Insulin Group (Type: EXPERIMENTAL): These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
- Exenatide + Insulin Group (Type: EXPERIMENTAL): This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
- Insulin monotherapy (Type: ACTIVE_COMPARATOR): This group will be on their regular insulin therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Rosuvastatin on Adenosine Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 - 50 years~* Signed informed consent~Exclusion Criteria:~* hypertension~* hypercholesterolemia~* diabetes Mellitus~* alanine aminotransferase \> 90 U/L~* creatinine Kinase \> 440 U/L~* cardiovascular disease~* GFR \< 80 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Is ≧ 18 years of age on the day of signing informed consent or other age required by local regulation~2. Willing and able to provide written informed consent~3. ESRD patients who is undergoing hemodialysis 3 times per week and is considered necessary to receive medication for hyperphosphatemia by his/her treating physician~4. Serum ferritin \<1000 ng/mL and transferrin saturation (TSAT) \< 50% at the Enrollment Visit~5. Women of child-bearing potential (WOCBP \[defined as women ≤ 50 years of age with a history of amenorrhea for \< 12 months prior to study entry\]) who is willing to use an effective form of contraception during study participation~Exclusion Criteria:~1. Has any known contraindication to ferric citrate according to locally approved prescribing information, include but not limited to the following criteria:~   i. Is allergic to ferric citrate ii. Has hypophosphatemia iii. Has hemochromatosis or iron overload syndromes iv. Has active severe GI disorders~2. Has parathyroidectomy (PTx) or percutaneous ethanol injection therapy (PEIT) within 3 months prior to Enrollment Visit or serum calcium \< 7 mg/dL at the Enrollment Visit~3. Has participated in another interventional study for any investigational agent or device within 30 days prior to enrollment~4. Is currently pregnant or breastfeeding~5. Other unstable medical condition or psychiatric conditions that is considered unsuitable for this study per Investigator's clinical judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric citrate (Type: EXPERIMENTAL): Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* must have received primary taxane and platinum-based chemotherapy and no more than 1 other chemotherapy regimen~* must have platinum resistant disease(defined as recurrence within 6 months of receiving platinum based chemotherapy, first or second line)~* must have measurable disease (greater than 20mm by conventional techniques or 10mm by spiral CT) OR elevated CA-125 (\> 100 on two occasions at least one week apart~* performance status greater than or equal to 70%~Exclusion Criteria:~* prior treatment with anti-angiogenesis agent~* treatment with \> 2 cytotoxic regimens (including primary platinum and taxane chemotherapy)~* evidence of other malignancy within 3 years of study enrollment~* history of abdominal fistula, grade 4 bowel obstruction or gastrointestinal perforation~* history of intra-abdominal abscess with 6 months prior to day 0~* pregnant or lactating patients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Tanezumab for Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~-Chronic low back pain ≥3 months in duration, Quebec Task Force in Spinal Disorders class 1 or 2, with documented history of previous inadequate treatment response to at least 3 different categories of agents commonly used and generally considered effective for the treatment of chronic low back pain.~Exclusion Criteria:~--Diagnosis of osteoarthritis of the knee or hip as defined by the American College of Rheumatology (ACR) criteria.~* Subjects who have Kellgren Lawrence Grade \> or =2 radiographic evidence of hip or Grade \> or=3 radiographic evidence of knee osteoarthritis will be excluded;~* History or radiographic evidence of other diseases that could confound efficacy or safety assessments (e.g., rheumatoid arthritis).~* History or radiographic evidence of orthopedic conditions that may increase the risk of, or confound assessment of joint safety conditions during the study.~* Signs and symptoms of clinically significant cardiac disease within 6 months of the study (e.g., unstable angina, myocardial infarction, resting bradycardia, poorly controlled or untreated hypertension) as defined in the protocol or subjects with any other cardiovascular illness that in the opinion of the Investigator would render a subject unsuitable to participate in the study~* History, diagnosis, or signs and symptoms of clinically significant neurological disease (e.g., transient ischemic attack, stroke, peripheral or autonomic neuropathy) as specified in the protocol~* Subjects with evidence or symptoms consistent with autonomic dysfunction (e.g., orthostatic hypotension and/or autonomic symptoms) as defined in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo to Week 16; tanezumab 5 mg SC (Type: PLACEBO_COMPARATOR): None
- Placebo to Week 16, tanezumab 10 mg SC (Type: PLACEBO_COMPARATOR): None
- Tanezumab 5 mg SC (Type: EXPERIMENTAL): None
- Tanezumab 10 mg SC (Type: EXPERIMENTAL): None
- Tramadol PR oral (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete